抄録_46回中国地方会37-6_責.indd

Size: px
Start display at page:

Download "抄録_46回中国地方会37-6_責.indd"

Transcription

1 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density 122 B A/B hypoechoic 75%/40%, hyperechoic 25%/60% P=0.001 MRI T1 A 6 25% B 69 57% P=0.004 EOB-MRI B 46-2 CTHA/CTAP 79 C CT MRI S4 4cm CTHA CTAP EOB-MRI TIWI T2WI Sonazoid US hypo echoic 30 2 iso echoic post vascular phase defect S4 US 46-3 planning sonography RVSCEUS RVS CEUS good 9 fair 28 poor 12 invisible 3 good RVS fair poor invisible RVS CEUS % 7.7% RVS CEUS 46-4 Sonazoid Sonazoid Sonazoid 15 Mechanical Index:0.2 focus TIC Sonazoid 0.010ml/kg TIC , PT BMI Spleen Index Sonazoid 46-5 Sonazoid CT 80mm

2 CT MRI Sonazoid 46-6 Sonazoid 70 B CT EOB-MRI Sonazoid Vascular phase Post-vascular phase Re-injection 6 5HIAA 46-7 Sonazoid DIC B Sonazoid CEUS defect 1 defect B Sonazoid CEUS mm FNH 3 10mm FNH CT S4 S5 S4 8-10mm B 3 central satellite scar spoke wheel appearance Sonazoid early arterial phase spoke wheel appearance late vascular phase Kupffer phase FNH HCC size FNH H21 5 H22 6 CT Sonazoid ml 5%EOI Hct 5.9% C AFP PIVKA 4 SOL 3 HCC S2 S2 10 US 12 CT US S2 S2 halo Sonazoid S2 S2 S2 HCC spleen index cm CT

3 2cm 21G PBC 22 2 S8 16mm Sonazoid early vascular phase late vascular phase Kupffer phase color doppler vascular phase penetrating vessel non-hodgkin lymphoma low grade B-cell lymphomapbc color doppler CT MRI hypovascular metastasis color Doppler 15 metastasis retrospective review B-mode color Doppler hypervascular CT MRI CT MRCP T-Bil3.7mg/dl ERCP EUS US hypovascular tumor EUSFNA US US US CT MRI ERCP 50% IgG4 IgG4 / EUS-FNA 1 46 LDH IgG US CT MRI DWI EUS capsule like rim ERCP EUS-FNA PET-CT FDG Burkitt lymphoma

4 DIC-CT 15mm EUS 2cm. 2cm ss 76 US 8mm 14mm EUS C 132 FibroScan Child Pugh Child Pugh P3P4 7s C C C 3 C FibroScan KPa HCV AdaBoost 12 8 Cross-Validation 56% 85% Virtual touch tissue quantification Virtual touch tissue quantification VTTQ (FIB4-index APRI VTTQ / 57/48 HBV/HCV 26/79 F cut off AUROC VTTQ; F1/2: F2/3; F3/4; FIB4;F1/2:17.13( F2/3: F3/4:46.7( APRI;F1/2: F2/3:9.93( F3/4:

5 0.552 VTTQ VTTQ C C C 66 TOSHIBA APLIO XG F -3, A1-3 HARI, HAPI, SARI, SAPI, PVVmean Alb AST ALT -GTP, PLT SAPI SARI SAPI AST ALT AST ALT Update EUS ESD EMR, ESD EUS EMR,ESD % % % % EMR, ESD m sm % 4 31% 3 75% 3 23% EUS EUS m 1mm sm 1mm m/sm EUS-m m/sm sm AD EUS-m 80.8% 194/240 EUS-sm 57.1% 28/49 8 EUS-m/sm 80.0% m 20.0% sm EUS mp se n=33 mp 4 5 ss 5 ss 5 se ss 5

6 CT free air 5 US 30mm SMA cm SMA SMA sandwich sign Castleman CT PET/CT 200cm 50cm myofibroblast CT MRI CT S 2cm 1 2cm X US S US 20 / 3 US US S - US S

7 46-34 US EUS Sonazoid US EUS US EUS FNA IPMN 14 mucus debris 1 NET 2 SPN 1 2 Sonazoid IPMN mm CT,MRI EUS-FNA 9 3 4cm CT Sonazoid EUS-FNA IPMN 70 45mm 8.5mm 3 9 MRI Sonazoid 15mm ERCP ENPD IPMC D paillary fibroelastoma 72 Debakey ,,aVF ST 2D flap CT STEMI 100% flow flow 3D 10mm 3D paillary fibroelastoma mm P mm

8 3D adenocarcinoma PET-CT FDG isoechoic 16 10mm 4 12 PET-CT RT area trace 70 80% PSV peak systolic velocity 2.5m/s 1.7m/s 80% PSV 4.6m/s 3.6m/s Cr Cr 6.3mg/dl PSV 90% PTA PSV Cr 8 1.3mg/dl PTA 12 Cr 1.3mg/dl MRA 3DCT D D dyssynchrony post systolic shortning 90% 2D

9 ,650/mm3 65%CRP 1.83mg/dl ESR 43/ CRP 3 7mg/dl CT H22 4 X effusion Myeloid/NK-cell acute leukemia effusion X CT A-aDO spontaneous echo contrast spontaneous echo contrast 1 9 spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast CPA XP shuffle motion Tei index Tei index 95%ile Tei index congenital absence of the portal vein: CAPV

10 26 16 CAPV CAPV 1031g AS5/7 CAPV three vessel view PGE1 17 BT 22q trisomy21 37 NICU trisomy % NICU g Apgar g Apgar8/ g Apgar Score8/ congenital pouch colon congenital pouch colon pouch colon g ph AFI 35cm 29 20ml/h ml g AS 1/5 Zimmerman-Laband

11 NST cm Tei index g As 1/3 Hb3.5mg/dl cm ,500ml MTX HCCRFA B-mode RFA CT margin B-mode Sonazoid RFA B-mode HCC TOSHIBA medical Aplio mode Sonazoid RFA CT CT RFA 1 RFA S8 15mm 1 RFA Sonazoid RFA 10ml 2 4 RFA CT S4 35 US 21G Majima needle Debris CT CT

12 4 US CT 5 US % US US VAS CT 15-20ml mm mm GF-UCT240-AL5 Echotip Wilson Cook 19G EUS 14 96% 26/27 15% 4/27 4% 1/ Carotidynia Carotidynia Carotidynia 1927 Fay 1967 Roseman 1988 the International Headache Society IHS classification committee 2004 Giant cell arteritis Carotidynia Carotidynia RVS US 3D CT-lymphography SLN Real-time virtual sonography RVS US CT SLN US SLN US SLN ICG SLN SLN % ICG SLN 9 ICG SLN US SLN SLN SLN SLN mm

13 20mm cm 2.0cm CT MRI T1WI T2WI IU/m FNAC classiv CT 15 CT MRI AVM AVM CT MRI AVM CT MRI AVM

抄録36-6偶_中国_責.indd

抄録36-6偶_中国_責.indd 45 21 9 12 1 45-1 3D 1 5 10 1 1 12 0 13 6 2D 2 2 3D 1 14 2 63g 11cm 2 3D x 3DCT 1 3D 45-2 FIUVV 3 10 FIUVV IUFD 2 FIUVV 33 35 MRI 36 8 22 1cm FIUVV 28 IUFD 45-3 Fetal intra-abdominal umbilical vein varixfiuv

More information

41-6_50回中国地方会Pr6N__HP掲載用.indd

41-6_50回中国地方会Pr6N__HP掲載用.indd 2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.

More information

084_41-1_23四国CS6_念*.indd

084_41-1_23四国CS6_念*.indd 2013 10 5 The forgotten chamber.,,,.1.2,,, 3,,. 4,CT,MRI,,,,,,,, fractional area change: FAC,,M tricuspid annular plane systolic excursion: TAPSE TAPSE < 16 mm., s, speckle tracking, Tei index,,,.,,,.,6,.,,,,,

More information

42-2_26回関東甲信越地方会Pr6N_念*.indd

42-2_26回関東甲信越地方会Pr6N_念*.indd 2014 10 18 19 TFT acoustic radiation force ARALA TI MI TI / MI TI / MI 1 2 3 4 5 1 2 3 4 5 PZT MASON 20 MRayl 20 MRayl 10 500 khz 20 MHz 1 mw 15 W 500 khz 20 MHz 100 W 60 MHz 1 2 3 4 5 4 6 6 4 1 2 3 4

More information

04_学術.indd

04_学術.indd Arts and Sciences 2 Diagnostic significance of contrast-enhanced ultrasonography for hepatocellular adenoma: experiences of two cases 41080 Key words: Abdominal ultrasonography Contrast-enhanced ultrasonography

More information

41-6_35回中部地方会Pr6N_HP掲載用.indd

41-6_35回中部地方会Pr6N_HP掲載用.indd ₃₅ 2014 9 7 ₃₅ ₁ 1, 1, 2, 1, 1, 1, 3, 3, 3 1, 2, 3., e E E/e. CT 158,CT Volume data, CT -140-40 HU. E e, e E/e. e,e/e,. ₃₅ ₂ 1, 1, 1, 1, 2, 2, 3, 2, 2 1, 2, 3 82, T,.. S, 13 mmhg,,, 10γ S 260 mmhg,. S,.,

More information

092_41-1_23九州CS6_責.indd

092_41-1_23九州CS6_責.indd 2013 10 6 1, 2 3 4, 5, 4, 6, 3, 5, 1, 1 1, 2, 3, 4, 5, 6,70. 2011 7 CT, B C, -GTP,CEA CA 19-9.US,S 2 / 3 43 37 mm,. 11 mm,,.ceus,.,.,. 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 52. S 7 20 mm,. CT, CT, EOB MRI,T

More information

₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3

₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 ₂₈ 2016 10 22 23 TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow. 3. 1 B Flow. 2,. 3. 3 1, 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3

More information

評価結果報告書の概要版(平成20年度)

評価結果報告書の概要版(平成20年度) 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

More information

03-07プ_一般口演_責*.indd

03-07プ_一般口演_責*.indd バブル キャビテーション 一 般 口 演 基 礎 5 月 9 日 ( 金 ) : 0-5 : 0 第 6 会 場 ( + ) 座 長 : 87- 基 -00 S6 87- 基 -00 S6 87- 基 -00 S65 87- 基 -00 S65 87- 基 -005 S66 組 織 音 響 特 性 5 月 9 日 ( 金 )5 : 50-7 : 00 第 6 会 場 ( + ) 座 長 : 87-

More information

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx 24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)

More information

169_39-2_23関東甲信越_念*.indd

169_39-2_23関東甲信越_念*.indd 2011 10 29 30 TFT infective endocarditis IE IE vegetation 10 20 IE IE Duke 1 1 1 1 2 2 1 2 1 1 5 US 1 mammography MMG 2 2 a second look US 0. 4 mm US b MMG 17 15 US MMG cse ASVascularity SE AS Vascularity

More information

抄録37-2関西36_責.indd

抄録37-2関西36_責.indd 36 21 10 3 36-D-1 36-D-2 / 36-D-3 Heart failure with preserved EF : HF-PEF EF S : 255 EF 45% HF-PEF n=45efs 50mm n=2551mm n=20 : EF S S : 7.0±1.1 vs. 5.3± 1.3 cm/s, p

More information

02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•

02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…• 8:55 9:00 19:00 9:32 29:32 10:04 AVF10:04 10:28 AVM10:28 11:00 111:00 11:24 211:24 11:48 12:00 13:10 13:10 13:20 13:20 14:20 14:20 14:30 14:30 14:46 14:46 15:10 115:10 15:42 215:42 16:14 16:14 9:00 9:24

More information

IVR232.indb

IVR232.indb IVR Jpn J Intervent Radiol 23, 2008. 1 1 71 2 1 3D CTA DSA direct CCF 5 1CCF CCF 3D CTA 24 17/70 1999 1999 5 2004 12 92 83 76/92 1 1.3 1/76 93 71/76 1 1.3 1/76 370 CT 3 1 C3 2 C6 3 C5 1 1 1 546 2 1 2 3

More information

S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2

S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2 vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.

More information

ÿþ

ÿþ YV-18 YV-19 YV-20 HALS Surgrx Enseal System 5 29 16:10 17:10 1-1 YP-1 YP-2 YP-3 YP-4 YP-5 YP-6 1 20 TS1 2 5 29 16:10 17:10 1-2 YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN 1 4 3 2 Gemcitabine 5 29 16:10 17:10

More information

200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,

More information

untitled

untitled 1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,

More information

049_41-1_43北海道CS6_念*.indd

049_41-1_43北海道CS6_念*.indd 25 10 19 11 : 00 18 : 00,,,,, Meyer et al. Circulation 2010;121:252-258,ASE J Am Soc Echocardiogr 2010;23:685-713., ASE 3 1, 10, 2 36, 3 38.ASE TAPSE,RVFAC,S. 1 / 2 / 3 TAPSE 8. 4 / 10. 0 / 24. 4 mm 16

More information

11 第25回がん学会一般演題一覧(第3会場)

11 第25回がん学会一般演題一覧(第3会場) 1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP

More information

04_ポスター.indb

04_ポスター.indb 般ポスター基礎超音波計測一般 一般ポスター基礎 6 月 8 日 ( 金 ):00 - :0 ポスター会場 ( 神戸ポートピアホテル B F 座長 : 9- 基 P-00 S790 9- 基 P-00 S790 9- 基 P-00 S79 Jing ZHU, 9- 基 P-00 S79 9- 基 P-005 S79 9- 基 P-006 CT S79 Wenjing WU 9- 基 P-007 HIFU

More information

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ , 24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998

More information

JSACHD_Vol5_No3_Dec2016.book

JSACHD_Vol5_No3_Dec2016.book 5 3 12 16 (2016 ) Fontan 1) 2) 1) 2) Fontan circulation, Fontan associated liver disease, Liver fibrosis, Liver tumor, Central venous Pressure 25% I. FALD Fontan Fontan ( CVP) Fontan associated liver disease

More information

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01 2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation

More information

パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71%

パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71% パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71% 第 49 回日本膵臓学会大会 2018.06.29. パネルディスカッション 2 症例 1 JA 尾道総合病院消化器内科 南智之, 花田敬士, 清水晃典, 福原基允, 横出正隆 Onomichi General

More information

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg 17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl

More information

デスフルラン

デスフルラン デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.

More information

59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1

59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1 59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl

More information

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate 37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

More information

がん診療におけるFDG FDG-PET/CTの役割

がん診療におけるFDG FDG-PET/CTの役割 PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT

More information

天草郡市医師会第139回(臨時)代議員会

天草郡市医師会第139回(臨時)代議員会 A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (

More information

01-表紙から目次.PDF

01-表紙から目次.PDF 56 100 1,205 45 11 30 48 56 56 10 56 1. 2 2. 2 3. 3 5 5 7 14 1 11 1. 11 (1) 11 (2) 11 (3) 11 (4) 12 (5) 12 2. 12 (1) 12 (2) 13 (3) 13 (4) 14 (5) 14 (6) 14 (7) 15 (8) 15 2 16 1. 16 (1) 16 (2) 17 (3) 17

More information

- 9 91, (2006)

- 9 91, (2006) Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM

More information

2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml

More information

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216

More information

10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11

More information

1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC 4.310 3 ml Syphilis TPAb Alb 2.7 g dl RBC30210 4 ml HBsAg T. bil 2.3 mg dl Hb 11 g dl

1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC 4.310 3 ml Syphilis TPAb Alb 2.7 g dl RBC30210 4 ml HBsAg T. bil 2.3 mg dl Hb 11 g dl 2012; 18: 200 207 Necropsy 1 1 1 2 65 11 autoimmune hepatitisaih 14 21 1 5 13 Necropsy CHF1 A1 Kupffer cell hemosiderin Berlin blue KEY WORDS: hemochromatosis, autoimmune hepatitis, liver cirrhosis, necropsy

More information

22肝胆膵_抄録_1_ indd

22肝胆膵_抄録_1_ indd 001 5 26 11:30 12:30 9-1 PO001-1 PO001-2 I II 2cm MRI PO001-3 PO001-4 PO001-5 PO001-6 5cm (Vp3/4,Vv2/3) PO001-7 1 PO001-8 B HCC C HCC B HCC PO001-9 002 5 26 11:30 12:30 9-1 PO002-1 HDAC PO002-2 Down Staging

More information

スライド 1

スライド 1 CT May 23, 2009 MDCT ~ 350 135mL ~ Clinical Experience with Highest Iodine Dose (630mgI/kg) of 135mL Syringe (Iomeprol 350mgI/mL) in Multiphasic MDCT of Liver Backgrounds A. multiphasic study for detecting

More information

福岡大学人文論叢47-3

福岡大学人文論叢47-3 679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.

More information

untitled

untitled 5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm

More information

PowerPoint Presentation

PowerPoint Presentation Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others

More information

GL_尾崎班_D.indd

GL_尾崎班_D.indd Circulation Journal Vol. 72, Suppl. IV, 2008 1319 Churg-Strauss ANCA ANCA 1 1 1320 Circulation Journal Vol. 72, Suppl. IV, 2008 ANCA 1 ANCA ANCA 2 Circulation Journal Vol. 72, Suppl. IV, 2008 1321 2 2

More information

indd

indd 18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

日本呼吸器学会雑誌第44巻第7号

日本呼吸器学会雑誌第44巻第7号 Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %

More information

_06.indd

_06.indd 30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,

More information

慈大呼吸器_25-1_02T_CS5.indd

慈大呼吸器_25-1_02T_CS5.indd ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40

More information

pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons

pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018

More information

被曝二世健康影響調査

被曝二世健康影響調査 19 3 1 1. 3 2. 4 4 4 6 7 8 8 3. 10 10 10 11 12 4. 14 14 15 15 15 15 16 17 17 18 18 19 19 5. 20 6. 21 22 2000 7 5 4 6 4 77,000 5mGy 5mGy 24,673 57.3 84.5% 11,951 BMI 1 - 1Gy 0.91 1Gy 0.98-48.6 48.4 19 10

More information

高脂血症の検査

高脂血症の検査 35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH

More information

PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 m

PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 m 2 2016 10 15 1, 2, 2, 2, 3, 3, 2, 4, 5, 4 1, 2, 3, 4, 5 I PH, PH PrePH PH PostPH, LVEF PostPH PEF-PostPH, PrePH PEF-PostPH, 25 mmhg, LVEF 45, 27, 15 mmhg PrePH 14 15 mmhg PEF-PostPH 13 TomTec 2D CPA, St

More information

次世代育成支援行動計画

次世代育成支援行動計画 15 7 10 300 9 17 21 5 21 22 5 1 2 3 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 16 39 40 11 2 3 P P 41 42 13 3 70.4 86.0 33.3 35.1 75.3 91.5 28.8 36.2 49.0 28.7 14.0 10.0

More information

: 1 : 50 mm : RCC 4 FFP ml 2. 1 : MRI : T2 6 cm flow void : Gd T1 UAE UAE 4 57

: 1 : 50 mm : RCC 4 FFP ml 2. 1 : MRI : T2 6 cm flow void : Gd T1 UAE UAE 4 57 34, 25-30, 2014 0.05 5.3% UAE TCR MTX 2013 7 1 11 31 4 1 36 1 1 2011 10 39 1 5 1 50 mm 1, MRI MRI T1 T2 flow void Gd T1 2, 50 UAE TCR 50 mm 700 ml 3 10 1 26 1. 1 : 1 : 50 mm : 3 2 36 4 2 2 2 13 49 RCC

More information

会場へのご案 内 駐車場のご用意がございませんので ご来場の際は 公共の交通機関等をご利用くださるよう お願い申しあげます 電車をご利用の場合 JR 横浜市営地下鉄線 桜木町駅下車 動く歩道利用 5 分 みなとみらい線 みなとみらい駅下車 クイーンズスクエア連絡口 けやき通り口 より徒歩 7 分 新

会場へのご案 内 駐車場のご用意がございませんので ご来場の際は 公共の交通機関等をご利用くださるよう お願い申しあげます 電車をご利用の場合 JR 横浜市営地下鉄線 桜木町駅下車 動く歩道利用 5 分 みなとみらい線 みなとみらい駅下車 クイーンズスクエア連絡口 けやき通り口 より徒歩 7 分 新 第 27 回 日本腹部造影エコー ドプラ診断研究会 (JACUA) プログラム 抄録集 日時 :2014 年 4 月 5 日 ( 土 ) 9:00 ~ 18:00 場 所 :はまぎんホールヴィアマーレ ( 横浜銀行本店ビル 1 階 ) TEL:045-225-2173 FAX:045-225-2183 代表世話人工藤正俊 第 ₂₇ 回当番世話人沼田和司 会場へのご案 内 駐車場のご用意がございませんので

More information

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6

112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6 Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6

More information

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10 . (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1

More information

07.報文_及川ら-二校目.indd

07.報文_及川ら-二校目.indd 8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006

More information

マニュアル第4版表紙PDF

マニュアル第4版表紙PDF 5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.

More information

「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について(第1報)」について

「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について(第1報)」について 2012 3 28 2011 3 1 1 2012 3 2012 3 28 2012 3 28 2012 3 28 2012 3 28 1. 1 3 11 1 2 3 15 17 3 4 5 1 2012 3 28 5 10 6 3 18 7 5 8 3 23 9 2 2012 3 28 2011 3 23 23 10 3 2012 3 28 4 2012 3 28 5 2012 3 28 3 24

More information

untitled

untitled 1 Session 1 9 00 10 00 10 4 1 1-001 CBCT 1-002 CT 1-003 FOV 1-004 Area detector CT 1-005 CT Modulation Transfer Function 1 2 3 4 5 6 7 8 1-006 CT Noise power spectrum 1 2 3 4 5 67 8 Session 2 10 00 10

More information

急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例

急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例 Japanese Society of Pulmonary Embolism Research -JaSPER- ) MAA 1964 WagnerIio Iio 1965 137 79 58 5715,1SD 99mTc MAA 81mKr discrete defectmpd MDP MPD MDP PH MPD MDP PH PH MDP patchinessmottled

More information

21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty

More information

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI 20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old

More information

30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM

30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM 29 大学院博士論文要旨 FIM? 櫻井 宏明 はじめに FIM Functional Independence Measure FIM ADL Activities of Daily Living FIM ADL 65 74 75 ADL 目的 FIM 方法 438 1 65 84 286 150 136 ADL FIM 3 FIM 30 60 90 120 FIM 44 0.7 3 Tukeykramer

More information

03_学術.indd

03_学術.indd Arts and Sciences PET/CT PET/CT System in The EMR and PACS hospital 1 24359 2 44769 1 2 Key words: (1) PET/CT, (2) EMR, (3) HIS, (4) RIS, (5) PACS Summary The PET/CT inspection was started under an electronic

More information

02-06プ_一般ポスター_0407.indd

02-06プ_一般ポスター_0407.indd 一般ポスター工学基礎一般ポスター工学基礎 イメージング 信号処理 5 月 7 日 ( 土 )6:0-7:0 ポスター 展示会場 座長 : ( 栃木県総合文化センター 階第 4 ギャラリー ) 90- 基 P-00 CT S6 90- 基 P-00 S6 90- 基 P-00 S6 90- 基 P-004 S6 90- 基 P-005 S64 90- 基 P-006 S64 90- 基 P-007 STC

More information

8 8 0

8 8 0 ,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

More information

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P 11 a. 2012 1 15 26 http://www1.koalanet.ne.jp/anesth_memorandum/sub19.html SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO2 20 30 8 10mL/kg I/E CPAP PEEP 27 b. CO2 ( ) SpO2 COPD PETCO2

More information

WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH

WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH 54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,

More information

S24-2411 S24-2211 S22-2321 S24-2421 S24-2311 20

S24-2411 S24-2211 S22-2321 S24-2421 S24-2311 20 TOSHIBA S24-2411 S24-2211 S22-2321 S24-2421 S24-2311 20 S24-3321 S24-3341 S24-3331 S24-3211 21 S24-3361 S24-3381 S24-3371 S24-3351 S24-3221 22 S25-5511 S24-5321 S24-5411 S24-5111 23 S24-5541 S24-5521 S24-5531

More information

02_特別_共同_奨励.indb

02_特別_共同_奨励.indb 特別プログラム 2 領域横断特別プログラム 知を究める領域横断 シンポジウム領域横断 超音波で全身を見る 6 月 8 日 ( 金 )0:5 - :45 第 9 会場 ( 神戸ポートピアホテル B F 偕楽 2) 座長 : 9 知 -SY- 領 0 S80 2 2 9 知 -SY- 領 02 S80 9 知 -SY- 領 0 S8 9 知 -SY- 領 04 S8 2 2 9 知 -SY- 領 05

More information

General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2)

General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2) General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2) (3) (4) (Standard Precautions ) (5) ( ) (6) (7) ( ) ( ) QOL(Quality of Life) ( ) (8) 1 2 (1) (2) (3) 4 24 (4) 3 ABC3 (common

More information

日本呼吸器学会雑誌第44巻第1号

日本呼吸器学会雑誌第44巻第1号 β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb

More information

- 1 -

- 1 - 19 21 - 1 - - 2 - - 3 - - 4 - 19 21 21 2224-5 - 19 2007 21 2009 H18 H27 18 27 10 H18 H22 18 22 22 H19 H21 19 21 21-6 - 20 21 19 2,449,254 2,495,506 1.9% 2,603,427 4.3% 1,593,428 1,582,704 0.7% 1,552,160

More information

Folie 1

Folie 1 low-b DWI IVIM,MSDE -- -- Makoto Obara Philips Electronics Japan Bfactor IVIM: Diffusion & Perfusion MSDE: Black Blood imaging IVIM: Diffusion & Perfusion MSDE: Black Blood imaging 40 2.5 * 10-3 mm 2 /sec

More information

051

051 Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

全国循環器撮影研究会 HP講座No

全国循環器撮影研究会 HP講座No HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased

More information

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1 11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

More information

051

051 June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS

More information

Contents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene

Contents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene Nalgene & Packaging plastic Bottles & Vials Contents 4 06 IP2 41 Thermo Scientific Nalgene 5 07 42 8 08 43 9 09 45 11 10 46 Nalgene 12 11 50 13 12 53 01 20 13 61 02 28 14 64 03 33 15 66 04 37 16 / 67 05

More information

32, 15, 3 EUS TIC 1 db,eus EG SR EUS 60, 27, 24 EUS EG SR 0. 11, , EUS EUS EG ₂₆ ₆ 1, 2, 1, 1, 3, 2, 4, 1 1, 2, 3, 4 FibroScan,

32, 15, 3 EUS TIC 1 db,eus EG SR EUS 60, 27, 24 EUS EG SR 0. 11, , EUS EUS EG ₂₆ ₆ 1, 2, 1, 1, 3, 2, 4, 1 1, 2, 3, 4 FibroScan, ₂₆ 2016 10 2 ₂₆ ₁ 1, 2, 2, 2, 2, 1, 2, 5, 3, 4 1, 2, 3, 4, 5., 491,. 491 339, 70 37 152 3, 339 2,.,. ₂₆ ₂ 1, 1, 1, 1, 1, 1, 2, 2, 1 1, 2 Müller MM, LVESVMM LVESV Ees DCM 20 15 CPX,LVESV, Ees,peak- VO 2

More information

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm

Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm CC junction Th1 swimmer s s position 15 Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm Log-roll 16 16 5.4 5.4 125 125 74.4 74.4 295 295 9 18.8 18.8 0 0 0 0 48 48 100 100 58 58 49.2 49.2 0 0 48 48

More information

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu

More information

( ) ー ( () ) 250 200 150 100 50 0 51 20 54 59 33 35 91 92 93 98 99 94 6 7 7 8 9 11 18 17 18 20 22 23 10 9 8 9 9 9 62 40 66 74 41 47 21 22 23 24 25 26 10 8 6 4 2 0 m3/s 7 41.3 5 5 18.4

More information

untitled

untitled Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb

More information

(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

(1) ) ) (2) (3) (4) (5) (1) (2) b (3).. ... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32

More information

日本呼吸器学会雑誌第47巻第6号

日本呼吸器学会雑誌第47巻第6号 Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.

More information